Secondary hormonal therapies in the treatment of prostate cancer.
about
Sirtuin 1 is required for antagonist-induced transcriptional repression of androgen-responsive genes by the androgen receptorHormonal impact of the 17alpha-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancerRepressive effects of resveratrol on androgen receptor transcriptional activity.CYP24A1 inhibition enhances the antitumor activity of calcitriol.Management of androgen-independent prostate cancer.Evaluating the use of early hormonal therapy in patients with localised or locally advanced prostate cancer.A phase I clinical study of high dose ketoconazole plus weekly docetaxel for metastatic castration resistant prostate cancer.The prognostic factors of effective ketoconazole treatment for metastatic castration-resistant prostate cancer: who can benefit from ketoconazole therapy?Optimizing the use of docetaxel in men with castration-resistant metastatic prostate cancer.Chemotherapy for prostate cancer: when should a urologist refer a patient to a medical oncologist?Targeting the relaxin hormonal pathway in prostate cancer.Clinical appraisal of abiraterone in the treatment of metastatic prostatic cancer: patient considerations, novel opportunities, and future directions.Microarray analysis of bicalutamide action on telomerase activity, p53 pathway and viability of prostate carcinoma cell lines.A phase II study of mifepristone (RU-486) in castration-resistant prostate cancer, with a correlative assessment of androgen-related hormones.Efficacy of nilutamide as secondary hormonal therapy in androgen-independent prostate cancer.Clinical outcome of maximum androgen blockade using flutamide as second-line hormonal therapy for hormone-refractory prostate cancer.
P2860
Q24306066-2A605AAB-AC35-4609-820C-C85682FD9D51Q24646000-3B63E085-D8DC-4269-87CF-BBF4A18C05ECQ33509527-B22EE1C1-2392-4A1E-965F-C9B464CCB01CQ34132307-C1AA1C85-6334-4BA5-8B50-17538FB262BEQ35996488-727F63A6-05A0-4405-80D8-DD55529535D3Q36106239-3F697F92-4764-4FB7-BBAF-4B736E876363Q36326889-F15F6774-CBCB-4DF2-AB88-D890E4F52A28Q37074125-D9E0FC96-C133-4C94-B930-266D67CF8543Q37672267-5094655D-3253-4F0B-9A84-DA6E7BA83B35Q38023123-BC22A07C-85A1-4DBF-9BA7-95582BF96D81Q38231840-CC77BA51-B964-4F37-A346-D094FAA201E2Q39485405-41B1B41B-009E-4A79-9846-53391990E726Q40473633-BC442906-683F-4DCE-B791-3F25E752C2A3Q46012889-DBF58DC9-5114-42F0-9A7B-BEE9DA131C6CQ46694969-127AB9FB-5A6B-4D0D-B11D-D88D4F3DA105Q46694974-651414AF-530F-4963-99D1-08B454553C82
P2860
Secondary hormonal therapies in the treatment of prostate cancer.
description
2002 nî lūn-bûn
@nan
2002 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Secondary hormonal therapies in the treatment of prostate cancer.
@ast
Secondary hormonal therapies in the treatment of prostate cancer.
@en
Secondary hormonal therapies in the treatment of prostate cancer.
@nl
type
label
Secondary hormonal therapies in the treatment of prostate cancer.
@ast
Secondary hormonal therapies in the treatment of prostate cancer.
@en
Secondary hormonal therapies in the treatment of prostate cancer.
@nl
prefLabel
Secondary hormonal therapies in the treatment of prostate cancer.
@ast
Secondary hormonal therapies in the treatment of prostate cancer.
@en
Secondary hormonal therapies in the treatment of prostate cancer.
@nl
P1433
P1476
Secondary hormonal therapies in the treatment of prostate cancer
@en
P2093
William K OH
P304
87-92; discussion 93
P356
10.1016/S0090-4295(02)01581-9
P407
P433
P577
2002-09-01T00:00:00Z